EquitySector - HealthcareVery High Risk
Direct
NAV (20-Jan-25)
Returns (Since Inception)
Fund Size
₹3,628 Cr
Expense Ratio
0.89%
ISIN
INF200K01UP2
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
01 Jan 2013
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+32.64%
+29.98% (Cat Avg.)
3 Years
+24.11%
+19.99% (Cat Avg.)
5 Years
+29.19%
+26.31% (Cat Avg.)
10 Years
+14.47%
+14.12% (Cat Avg.)
Since Inception
+18.77%
— (Cat Avg.)
Equity | ₹3,503.5 Cr | 96.57% |
Debt | ₹2.92 Cr | 0.08% |
Others | ₹121.62 Cr | 3.35% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹471.59 Cr | 13.00% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹225.63 Cr | 6.22% |
Divi's Laboratories Ltd | Equity | ₹219.56 Cr | 6.05% |
Cipla Ltd | Equity | ₹214.06 Cr | 5.90% |
Lupin Ltd | Equity | ₹188.46 Cr | 5.19% |
Lonza Group Ltd ADR | Equity | ₹150.99 Cr | 4.16% |
Mankind Pharma Ltd | Equity | ₹150.65 Cr | 4.15% |
Poly Medicure Ltd | Equity | ₹130.76 Cr | 3.60% |
Treps | Cash - Repurchase Agreement | ₹130.09 Cr | 3.59% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹125.58 Cr | 3.46% |
Jupiter Life Line Hospitals Ltd | Equity | ₹125.02 Cr | 3.45% |
Aether Industries Ltd | Equity | ₹124.17 Cr | 3.42% |
Ami Organics Ltd | Equity | ₹112.81 Cr | 3.11% |
Fortis Healthcare Ltd | Equity | ₹107.98 Cr | 2.98% |
Abbott India Ltd | Equity | ₹107.07 Cr | 2.95% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹102.79 Cr | 2.83% |
Torrent Pharmaceuticals Ltd | Equity | ₹100.8 Cr | 2.78% |
Aurobindo Pharma Ltd | Equity | ₹100.09 Cr | 2.76% |
Gland Pharma Ltd | Equity | ₹96.08 Cr | 2.65% |
Rainbow Childrens Medicare Ltd | Equity | ₹95.97 Cr | 2.65% |
Alkem Laboratories Ltd | Equity | ₹84.51 Cr | 2.33% |
Laurus Labs Ltd | Equity | ₹72.32 Cr | 1.99% |
Biocon Ltd | Equity | ₹65.76 Cr | 1.81% |
Vijaya Diagnostic Centre Ltd | Equity | ₹63.41 Cr | 1.75% |
Suven Pharmaceuticals Ltd | Equity | ₹61.49 Cr | 1.69% |
Akums Drugs and Pharmaceuticals Ltd | Equity | ₹53.15 Cr | 1.46% |
Gufic Biosciences Ltd | Equity | ₹45.53 Cr | 1.25% |
Pfizer Ltd | Equity | ₹39.61 Cr | 1.09% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹36.96 Cr | 1.02% |
Dr. Lal PathLabs Ltd | Equity | ₹30 Cr | 0.83% |
Net Receivable / Payable | Cash - Collateral | ₹-8.47 Cr | 0.23% |
182 DTB 05062025 | Bond - Gov't/Treasury | ₹2.92 Cr | 0.08% |
Concord Biotech Ltd | Equity | ₹0.69 Cr | 0.02% |
Large Cap Stocks
31.88%
Mid Cap Stocks
26.89%
Small Cap Stocks
31.15%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹3,266.51 Cr | 90.04% |
Basic Materials | ₹236.99 Cr | 6.53% |
Standard Deviation
This fund
14.25%
Cat. avg.
15.72%
Lower the better
Sharpe Ratio
This fund
1.17
Cat. avg.
0.87
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.61
Higher the better
Since June 2011
Since December 2023
ISIN INF200K01UP2 | Expense Ratio 0.89% | Exit Load No Charges | Fund Size ₹3,628 Cr | Age 12 years | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹31.91 Cr | 30.7% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹890.33 Cr | 23.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹890.33 Cr | 21.6% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹44.16 Cr | 28.7% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹230.79 Cr | 30.0% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹230.79 Cr | 27.5% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2863.52 Cr | 29.0% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2863.52 Cr | 27.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹922.81 Cr | 27.4% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹20.52 Cr | 28.5% |
Total AUM
₹10,87,953 Cr
Address
C-38 & 39, G Block, Bandra Kurla Complex, Mumbai, 400 051
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Direct
NAV (20-Jan-25)
Returns (Since Inception)
Fund Size
₹3,628 Cr
Expense Ratio
0.89%
ISIN
INF200K01UP2
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
01 Jan 2013
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+32.64%
+29.98% (Cat Avg.)
3 Years
+24.11%
+19.99% (Cat Avg.)
5 Years
+29.19%
+26.31% (Cat Avg.)
10 Years
+14.47%
+14.12% (Cat Avg.)
Since Inception
+18.77%
— (Cat Avg.)
Equity | ₹3,503.5 Cr | 96.57% |
Debt | ₹2.92 Cr | 0.08% |
Others | ₹121.62 Cr | 3.35% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹471.59 Cr | 13.00% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹225.63 Cr | 6.22% |
Divi's Laboratories Ltd | Equity | ₹219.56 Cr | 6.05% |
Cipla Ltd | Equity | ₹214.06 Cr | 5.90% |
Lupin Ltd | Equity | ₹188.46 Cr | 5.19% |
Lonza Group Ltd ADR | Equity | ₹150.99 Cr | 4.16% |
Mankind Pharma Ltd | Equity | ₹150.65 Cr | 4.15% |
Poly Medicure Ltd | Equity | ₹130.76 Cr | 3.60% |
Treps | Cash - Repurchase Agreement | ₹130.09 Cr | 3.59% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹125.58 Cr | 3.46% |
Jupiter Life Line Hospitals Ltd | Equity | ₹125.02 Cr | 3.45% |
Aether Industries Ltd | Equity | ₹124.17 Cr | 3.42% |
Ami Organics Ltd | Equity | ₹112.81 Cr | 3.11% |
Fortis Healthcare Ltd | Equity | ₹107.98 Cr | 2.98% |
Abbott India Ltd | Equity | ₹107.07 Cr | 2.95% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹102.79 Cr | 2.83% |
Torrent Pharmaceuticals Ltd | Equity | ₹100.8 Cr | 2.78% |
Aurobindo Pharma Ltd | Equity | ₹100.09 Cr | 2.76% |
Gland Pharma Ltd | Equity | ₹96.08 Cr | 2.65% |
Rainbow Childrens Medicare Ltd | Equity | ₹95.97 Cr | 2.65% |
Alkem Laboratories Ltd | Equity | ₹84.51 Cr | 2.33% |
Laurus Labs Ltd | Equity | ₹72.32 Cr | 1.99% |
Biocon Ltd | Equity | ₹65.76 Cr | 1.81% |
Vijaya Diagnostic Centre Ltd | Equity | ₹63.41 Cr | 1.75% |
Suven Pharmaceuticals Ltd | Equity | ₹61.49 Cr | 1.69% |
Akums Drugs and Pharmaceuticals Ltd | Equity | ₹53.15 Cr | 1.46% |
Gufic Biosciences Ltd | Equity | ₹45.53 Cr | 1.25% |
Pfizer Ltd | Equity | ₹39.61 Cr | 1.09% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹36.96 Cr | 1.02% |
Dr. Lal PathLabs Ltd | Equity | ₹30 Cr | 0.83% |
Net Receivable / Payable | Cash - Collateral | ₹-8.47 Cr | 0.23% |
182 DTB 05062025 | Bond - Gov't/Treasury | ₹2.92 Cr | 0.08% |
Concord Biotech Ltd | Equity | ₹0.69 Cr | 0.02% |
Large Cap Stocks
31.88%
Mid Cap Stocks
26.89%
Small Cap Stocks
31.15%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹3,266.51 Cr | 90.04% |
Basic Materials | ₹236.99 Cr | 6.53% |
Standard Deviation
This fund
14.25%
Cat. avg.
15.72%
Lower the better
Sharpe Ratio
This fund
1.17
Cat. avg.
0.87
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.61
Higher the better
Since June 2011
Since December 2023
ISIN INF200K01UP2 | Expense Ratio 0.89% | Exit Load No Charges | Fund Size ₹3,628 Cr | Age 12 years | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹31.91 Cr | 30.7% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹890.33 Cr | 23.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹890.33 Cr | 21.6% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹44.16 Cr | 28.7% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹230.79 Cr | 30.0% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹230.79 Cr | 27.5% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2863.52 Cr | 29.0% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2863.52 Cr | 27.2% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹922.81 Cr | 27.4% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹20.52 Cr | 28.5% |
Total AUM
₹10,87,953 Cr
Address
C-38 & 39, G Block, Bandra Kurla Complex, Mumbai, 400 051
Get your portfolio reviewed by experts